Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 4, 2005, Pages 450-455

  Fagerberg, Ulrika Lorentzon ^a,b,c   Lööf, Lars ^b   Myrdal, Urban ^b   Hansson, Lars Olof ^c   Finkel, Yigael ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calprotectin; Children; Colitis; Feces; Inflammatory bowel disease

Indexed keywords

CALPROTECTIN;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COLON DISEASE; COLON POLYPOSIS; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIARRHEA; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATION; LABORATORY TEST; MALE; NEUTROPHIL; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; COLONOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 16844377257     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MPG.0000154657.08994.94     Document Type: Article

References (33)

1. Aadland E, Fagerhol MK. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823-5.
2. Fagerhol MK, Andersson KB, Naess-Andresen CF, et al. Calprotectin (The L1 leukocyte protein). In: Smith VL, Dedman JR, eds. Stimulus Response Coupling: The Role of Intracellular Calcium Binding Proteins. Boca Raton: CRC Press; 1990:187-210.
3. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol 1980;24:393-8.
4. Røseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
5. Johne B, Kronborg O, Tøn HI, et al. A new fecal calprotectin test for colorectal neoplasia. Scand J Gastroenterol 2001;36:291-6.
6. Røseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces: A methodologic study. Scand J Gastroenterol 1992;27:793-8.
7. Røseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocyten and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
8. Tibble J, Teahon K, Thjordleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
9. Bunn SK, Bisset WM, Main MJC, et al. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171-7.
10. Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
11. Bunn SK, Bisset WM, Main MJC, et al. Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
12. Tøn H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
13. Fagerberg UL, Lööf L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37:468-72.
14. Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004;89:69-71.
15. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-7.
16. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 2002;123:450-60.
17. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Pædiatr 2002;91:45-50.
18. Carroccio A, Iacono G. Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin Chem 2003;49:861-7.
19. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroeterol Nutr 2002;34:323-4.
20. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64-9.
21. Bjarnason I, Macphearson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566-81.
22. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14:409-12.
23. Catassi C, Cardinali E, D'Angelo G, et al. Reliability of random fecal α1-antitrypsin determination on nondried stools. J Pediatr 1986;109:500-2.
24. Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997;42:394-403.
25. Braegger CP, Nicholls S, Murch SH. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
26. Becker K, Niederau C, Frieling T. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease. Z Gastroenterol 1999;37:597-605.
27. Ljung T, Beijer E, Herulf M, et al. Increased rectal nitric oxide in children with active inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34:302-6.
28. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-34.
29. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
30. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
31. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6.
32. Poullis A, Foster R, Mendall MA. Proton pump inhibitors are associated with elevation of fecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003;15:573-4.
33. Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7.